• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Patients with HER2-positive advanced breast cancer and pathological complete response to neoadjuvant systemic therapy may not require surgical intervention

byKassandra McFarlaneandSze Wah Samuel Chan
October 31, 2022
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with pathological complete response to neoadjuvant systemic therapy, there was no tumour recurrence at 2 years

2. No adverse events or deaths occurred secondary to vacuum-assisted core biopsy, used to determine extent of pathological response to treatment

Evidence Rating Level: 2 (Good)

Study Rundown: Prior studies have found that patients with HER2-positive breast cancer receiving neoadjuvant systemic therapy (NST) have a high rate of pathological complete response, which can be assessed using vacuum-assisted core biopsy (VACB). This study investigated radiotherapy as the sole treatment following initial standardized NST treatment with evidence of pathological complete response. The rate of recurrence of breast cancer tumour was a primary outcome of this study, while safety of VACB was a secondary outcome. A pathological complete response was identified by VACB in 31 of 50 patients and at the 2-year follow-up period, none had experienced tumour recurrence. For the VACB procedure itself, only 2 of 50 patients experienced any adverse effects; one had nausea which resolved on its own and one patient was minimally affected by equipment malfunction with no adverse event. Limitations to this study include the small sample size, and due to a potential for delayed tumour recurrence in HER-2 positive advanced breast cancers, there should be caution if considering this early data for clinical decision making. Overall, the results from this study suggest that additional trials investigating avoiding surgical intervention in HER2-positive advanced breast cancer with complete pathological response to NST will be worthwhile.

Click to read the study in The Lancet Oncology

Relevant Reading: Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges

In-Depth [randomized controlled trial]: This single-arm, phase 2 trial was performed in multiple centres in the United States. This study included data from 50 female patients that were 40 years or older with confirmed HER2-positive invasive breast cancer and who had received neoadjuvant systemic therapy. The study was completed in 2 stages – a feasibility phase and an expansion cohort phase. During the feasibility stage, 6 patients were provided treatment with NST and monitored for 6 months for tumour recurrence to determine treatment plan safety. During the expansion phase, 31 of 50 (62%) patients were found to have pathological complete response (95% confidence interval (CI), 47.2 – 75.4%). Of these patients, none experienced recurrence of ipsilateral tumour after 2 years (median follow-up 26.4 months (interquartile range, 15.2 – 39.6 months)). Minimal negative events occurred during the VACB procedures, and no adverse events or deaths were reported.

RELATED REPORTS

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Religious-based interventions improve illness perception in breast cancer patients

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast CancerHer2neoadjuvant chemotherapy
Previous Post

COVID-19 vaccination is safe during pregnancy and has benefits for neonatal outcomes

Next Post

Apixaban is superior to rivaroxaban in patients with atrial fibrillation and valvular heart disease

RelatedReports

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
StudyGraphics

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

January 31, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
Palliative care consultation linked to lower deaths by failed code resuscitation
Oncology

Religious-based interventions improve illness perception in breast cancer patients

January 9, 2023
Early palliative care may improve survival in advanced cancer
Wellness

Wellness Check: Spirituality

January 5, 2023
Next Post
Quick Take: Left ventricular mechanical dispersion predicts arrhythmic risk in mitral valve prolapse

Apixaban is superior to rivaroxaban in patients with atrial fibrillation and valvular heart disease

Patient Basics: Enlarged Prostate (Benign Prostatic Hyperplasia)

Sequencing of androgen-deprivation therapy with radiotherapy for non-metastatic prostate cancer

Large proportion of late preterm infants and older admitted to the NICU

Neonatal docosahexaenoic acid supplementation is associated with higher IQ scores at five years of age

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options